These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32368733)

  • 21. Meta-Analysis of Cognition in Parkinson's Disease Mild Cognitive Impairment and Dementia Progression.
    Wallace ER; Segerstrom SC; van Horne CG; Schmitt FA; Koehl LM
    Neuropsychol Rev; 2022 Mar; 32(1):149-160. PubMed ID: 33860906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia.
    Galtier I; Nieto A; Lorenzo JN; Barroso J
    J Clin Exp Neuropsychol; 2016; 38(1):40-50. PubMed ID: 26602176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. White matter damage in patients with mild cognitive impairment in Parkinson's disease.
    Li QQ; Wu K; Xu JL; Yin L
    Quant Imaging Med Surg; 2022 Feb; 12(2):1290-1298. PubMed ID: 35111624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.
    Lucza T; Karádi K; Kállai J; Weintraut R; Janszky J; Makkos A; Komoly S; Kovács N
    Behav Neurol; 2015; 2015():983606. PubMed ID: 26078489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis.
    Ciesielska N; Sokołowski R; Mazur E; Podhorecka M; Polak-Szabela A; Kędziora-Kornatowska K
    Psychiatr Pol; 2016 Oct; 50(5):1039-1052. PubMed ID: 27992895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity.
    Snyder A; Gruber-Baldini AL; Rainer von Coelln F; Savitt JM; Reich SG; Armstrong MJ; Shulman LM
    J Parkinsons Dis; 2021; 11(4):1995-2003. PubMed ID: 34366371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment.
    Simon-Gozalbo A; Rodriguez-Blazquez C; Forjaz MJ; Martinez-Martin P
    Front Neurol; 2020; 11():731. PubMed ID: 32849203
    [No Abstract]   [Full Text] [Related]  

  • 28. Can the prediction model using regression with optimal scale improve the power to predict the Parkinson's dementia?
    Byeon H
    World J Psychiatry; 2022 Aug; 12(8):1031-1043. PubMed ID: 36158303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.
    Nazem S; Siderowf AD; Duda JE; Have TT; Colcher A; Horn SS; Moberg PJ; Wilkinson JR; Hurtig HI; Stern MB; Weintraub D
    J Am Geriatr Soc; 2009 Feb; 57(2):304-8. PubMed ID: 19170786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease.
    Scheffels JF; Fröhlich L; Kalbe E; Kessler J
    J Neurol Sci; 2020 May; 412():116735. PubMed ID: 32087430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis of possible mild cognitive impairment in Parkinson's disease: validity of the SCOPA-Cog.
    Isella V; Mapelli C; Morielli N; Siri C; De Gaspari D; Pezzoli G; Antonini A; Poletti M; Bonuccelli U; Picchi L; Napolitano A; Vista M; Appollonio IM
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1160-3. PubMed ID: 24011719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates.
    Chou KL; Lenhart A; Koeppe RA; Bohnen NI
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1076-80. PubMed ID: 25085750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients.
    Sulzer P; Becker S; Maetzler W; Kalbe E; van Nueten L; Timmers M; Machetanz G; Streffer J; Salvadore G; Scholz E; Tkaczynska Z; Brockmann K; Berg D; Liepelt-Scarfone I
    J Neurol; 2018 Sep; 265(9):1976-1984. PubMed ID: 29936665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment.
    Fernández de Bobadilla R; Pagonabarraga J; Martínez-Horta S; Pascual-Sedano B; Campolongo A; Kulisevsky J
    Mov Disord; 2013 Sep; 28(10):1376-83. PubMed ID: 23873810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Criterion and convergent validity of the Montreal cognitive assessment with screening and standardized neuropsychological testing.
    Lam B; Middleton LE; Masellis M; Stuss DT; Harry RD; Kiss A; Black SE
    J Am Geriatr Soc; 2013 Dec; 61(12):2181-2185. PubMed ID: 24320735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.
    Burdick DJ; Cholerton B; Watson GS; Siderowf A; Trojanowski JQ; Weintraub D; Ritz B; Rhodes SL; Rausch R; Factor SA; Wood-Siverio C; Quinn JF; Chung KA; Srivatsal S; Edwards KL; Montine TJ; Zabetian CP; Leverenz JB
    Mov Disord; 2014 Sep; 29(10):1258-64. PubMed ID: 25073717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
    Hendershott TR; Zhu D; Llanes S; Zabetian CP; Quinn J; Edwards KL; Leverenz JB; Montine T; Cholerton B; Poston KL
    Mov Disord; 2019 Feb; 34(2):285-291. PubMed ID: 30776152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort.
    Lawson RA; Williams-Gray CH; Camacho M; Duncan GW; Khoo TK; Breen DP; Barker RA; Rochester L; Burn DJ; Yarnall AJ;
    J Parkinsons Dis; 2021; 11(3):1297-1308. PubMed ID: 34024781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study.
    Nicoletti A; Luca A; Baschi R; Cicero CE; Mostile G; Davì M; La Bianca G; Restivo V; Zappia M; Monastero R
    J Neurol; 2021 Feb; 268(2):549-558. PubMed ID: 32865628
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.